Trial Profile
A multi-institutional double-blind phase II study evaluating response and surrogate biomarkers to carboplatin and Nab-paclitaxel (CP) with or without vorinostat as preoperative chemotherapy in HER2 negative primary operable breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Carboplatin; Paclitaxel
- Indications Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 02 Feb 2024 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.
- 01 Feb 2023 Planned End Date changed from 1 Feb 2023 to 1 Feb 2024.
- 27 Jan 2022 Planned End Date changed from 1 Feb 2022 to 1 Feb 2023.